The results demonstrated TPD52L2 upregulation in gastric carcinoma cells (resistant to OXA) which suggests that TPD52L2 has a potential role in OXA resistance chemotherapy in gastric carcinoma. The gene discussed is TPD52L2; the disease is gastric carcinoma.